DH · Definitive Healthcare Corp.
Market Cap
$100.27M
Shares
106.74M
Volume · Oct 5
164.48K
Avg daily vol (3M)
593.45K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.93
Open$0.94
Day$0.93–0.96
52W close$0.63–3.42
Avg vol 30d1.0M
Short int1.8M · 1.7% float · 1.3d
Short vol38%
Last earningsAug 10, 2026
DataSep 2021–Oct 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 5 wks
filed Aug 10, 2026
call held Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-72.0%
Trailing year
Short interest
1.7%
Latest settlement · 1.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
+12%
above
RSI (14)
52
neutral
MACD trend
Negative
52-week position
11%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−6%
trailing
YTD return
−67%
this year
Relative strength
−18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-17% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.71% of float · ▼ -8.3% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
99 holders — near 3-yr low, contrarian setup
Squeeze score
43
elevated · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
Gross margin
76%
contracting
EPS growth
+63%
Y/Y
Free cash flow
$37.1M
Buyback
$120.0M
authorized
Balance sheet
$1.2M
net debt
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−82%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 10, 2026
Q3
Total revenue
$54M – $55M
prior qtr $55.2M
midpoint −1.3% QoQ
Adjusted operating income
Non-GAAP
$10.5M – $11.5M
Adjusted EBITDA
Non-GAAP
$13.5M – $14.5M
Adjusted earnings per diluted share
Non-GAAP
$0.05
Adjusted net income
Non-GAAP
$5.5M – $6.5M
full year 2026
Revenue
Initiated
$220M – $222M
prior FY $241.52M
midpoint −8.5% Y/Y
Adjusted operating income
Non-GAAP
Initiated
$45.5M – $47.5M
Adjusted EBITDA
Non-GAAP
Initiated
$57M – $59M
Guided vs delivered
· last 8 settled
Revenue
Third Quarter 2024
guided $61M – $62.5M
$62.7M
Beat +1.5%
Revenue
Full Year 2024
guided $247M – $251M
$252.2M
Beat +1.3%
Revenue
Second Quarter 2024
guided $62M – $63.5M
$63.74M
Beat +1.6%
Revenue
First Quarter 2024
guided $63M – $65M
$63.48M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
+12%
Bullish
RSI (14)
52
Neutral
MACD trend
Negative
Bearish
52-week position
11%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-17% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.71% of float · ▼ -8.3% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
99 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 11%
Range high $3
vs 200-day avg -24%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA and margin non-GAAP | 29.95M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 26% | Q2 2026 | — |
| Adjusted Gross Margin non-GAAP | 80% | Six Months Ended June 30 | — |
| Adjusted Gross Profit non-GAAP | 89.38M | Six Months Ended June 30 | — |
| Adjusted Net Income non-GAAP | 16.03M | Six Months Ended June 30 | — |
| Adjusted Net Income Per Share non-GAAP | $0.11 | Six Months Ended June 30 | — |
| Adjusted Operating Income non-GAAP | 24.73M | Six Months Ended June 30 | — |
| Unlevered Free Cash Flow non-GAAP | 29.57M | Six Months Ended June 30 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DH
this stock
Definitive Healthcare Corp.
|
$100.27M | -67.5% | -4.2% | — | 1.7% |
|
VEEV
Veeva Systems Inc
|
$45.44B | +22.4% | +28.1% | 45.9 | 3.1% |
|
TEM
Tempus AI, Inc.
|
$15.34B | +29.8% | +83.4% | — | 15.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.20B | -29.7% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.02B | +60.9% | +28.2% | 33.8 | 5.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DH | -1.2% | -10.3% | -5.9% | +3.1% | -67.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -1.0% | -9.8% | -18.1% | +2.2% | -80.3% |
Capital returns
Buyback programs
· 2 active
· as of Nov 1, 2024
Authorized (total)
$120.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.